Ucb S A (UCBJF) 78.5000 $UCBJF UCB (UCBJF) Posts 1H16

New Post Public Reply Private Reply Replies (0) Message Board

Aug 14, 2016 at 3:13 AM

Ucb S A (UCBJF) 78.5000 $UCBJF

UCB (UCBJF) Posts 1H16 Results, Reaffirms 2016 Guidance
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 9:15AM CDT
UCB (UCBJF) reported results for the first half of 2016.
BIIB: 313.94 (-0.55), AMGN: 173.02 (+0.59), NKTR: 17.16 (-0.05)

Dr. Reddy's (RDY) Acquires Ducere Pharma's OTC Brands
Zacks Equity Research - Zacks Investment Research - Thu May 26, 2:57PM CDT
Dr. Reddy's Laboratories Ltd. (RDY) announced that it acquired a portfolio of OTC brands in the cough-and-cold, pain, and dermatology categories from Ducere Pharma.
ABT: 45.04 (-0.01), JNJ: 123.22 (-0.55), RDY: 44.82 (unch)

UCB (UCBJF) Posts Q1 Results, Reiterates 2016 Guidance
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 10:23AM CDT
UCB (UCBJF) reported interim results for the first three months of 2016.
EBS: 26.87 (-0.73), GILD: 79.66 (+0.09), SHPG: 198.93 (+0.19)

UCB: CONVENING NOTICE TO ATTEND THE GENERAL MEETING OF SHAREHOLDERS
Globe Newswire - Fri Mar 25, 3:01AM CDT
*** Unofficial English translation - For convenience purposes only ***

Dr. Reddy's Q3 Earnings Up Y/Y, Warning Letter in Focus
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 10:06AM CST
Dr. Reddy's Laboratories Ltd. (RDY) reported third-quarter fiscal 2016 earnings per American Depositary Share of 51 cents, up 1% from the year-ago quarter.
ATRA: 21.22 (+0.10), BXLT: 46.02 (-0.18), RDY: 44.82 (unch)

ZS Pharma Soars on $2.7B Buyout Offer from AstraZeneca
Zacks Equity Research - Zacks Investment Research - Mon Nov 09, 11:50AM CST
AstraZeneca (AZN) will acquire biotech company ZS Pharma (ZSPH) for about $2.7 billion, boosting its cardiovascular & metabolic disease portfolio and pipeline.
ZSPH: 89.98 (+0.06), AZN: 33.54 (-0.27)

Aerie (AERI) Posts Narrower-than-Expected Loss in Q3
Zacks Equity Research - Zacks Investment Research - Wed Nov 04, 9:40AM CST
Aerie (AERI) reported third-quarter 2015 loss of 69 cents per share, much narrower than the Zacks Consensus Estimate of a loss of 81 cents.
ADHD: 5.01 (+0.01), AERI: 18.43 (+0.48), SPPI: 5.81 (-0.10)

Dr. Reddy's (RDY) Q2 Earnings Rise Y/Y, Biosimilars in Focus
Zacks Equity Research - Zacks Investment Research - Fri Oct 30, 10:16AM CDT
Dr. Reddy's Laboratories (RDY) reported second-quarter fiscal 2016 earnings per American Depositary Share (ADS) of 64 cents, up 25.5% from the year-ago quarter.
ANAC: 99.06 (-0.14), RDY: 44.82 (unch), CORT: 5.77 (-0.05)

Valeant (VRX) Loses Over 5% Despite Business Model Review
Zacks Equity Research - Zacks Investment Research - Tue Oct 27, 1:22PM CDT
Investigations into Valeant's (VRX) drug pricing policies and accusations related to its business model continue. The company has an uphill battle ahead.
LCI: 31.36 (-0.34), VRX: 24.92 (+0.43), ANAC: 99.06 (-0.14)

Valeant (VRX) in Focus on Intensifying Government Probe
Zacks Equity Research - Zacks Investment Research - Fri Oct 16, 1:20PM CDT
Valeant (VRX) has hit a rough patch ever since concerns arose about the irrational increase in drug prices by U.S. pharma/biotech companies.
LCI: 31.36 (-0.34), VRX: 24.92 (+0.43), ANAC: 99.06 (-0.14)

Prothena to Start Phase IIb Study on AL Amyloidosis Drug
Zacks Equity Research - Zacks Investment Research - Fri Oct 16, 1:10PM CDT
Prothena (PRTA) announced that it will commence a phase IIb study on NEOD001 for patients suffering from AL amyloidosis and persistent cardiac dysfunction.
LCI: 31.36 (-0.34), ANAC: 99.06 (-0.14), PRTA: 57.79 (+1.07)

Shire's Cinryze Gets Fast Track Status for Additional Indication
Zacks Equity Research - Zacks Investment Research - Wed Oct 14, 2:45PM CDT
Shire announced that its HAE drug Cinryze has been granted Fast Track designation for antibody mediated rejection (AMR) in renal transplant recipients by the FDA.
LCI: 31.36 (-0.34), SHPG: 198.93 (+0.19), AZN: 33.54 (-0.27)

UCB Reveals Positive Data on Vimpat Monotherapy Study
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 1:45PM CDT
UCB (UCBJF) announced encouraging top-line results from a phase III non-inferiority study on Vimpat monotherapy for newly diagnosed partial-onset seizures.
ADHD: 5.01 (+0.01), APRI: 0.30 (unch), ANAC: 99.06 (-0.14)

Catalyst Starts Congenital Myasthenic Syndromes Study
Zacks Equity Research - Zacks Investment Research - Wed Oct 07, 1:35PM CDT
Catalyst Pharmaceuticals (CPRX) initiated a pediatric study on Firdapse for congenital myasthenic syndromes in patients aged 2 years to 17 years.
BMRN: 92.44 (+0.43), CPRX: 0.74 (-0.01), APRI: 0.30 (unch)

Lannett (LCI) to Buy UCB's Specialty Generics Subsidiary
Zacks Equity Research - Zacks Investment Research - Thu Sep 03, 3:10PM CDT
Lannett Company (LCI) inked a deal with UCB to buy its U.S. specialty generics subsidiary, Kremers Urban Pharmaceuticals Inc.
LCI: 31.36 (-0.34), JNJ: 123.22 (-0.55), CORT: 5.77 (-0.05)

Amgen, Novartis Team Up; Bone Drug Positive in Phase III
Zacks Equity Research - Zacks Investment Research - Wed Sep 02, 3:50PM CDT
Amgen (AMGN) inks deal with Novartis for Alzheimer's disease and migraine; reports positive phase III data on romosozumab.
AMGN: 173.02 (+0.59), LLY: 80.22 (-0.34), NVS: 82.08 (-0.72)

Dr. Reddy's Q1 Earnings & Revenues Rise Y/Y, Offers View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 31, 2:07PM CDT
Dr. Reddy's Laboratories (RDY) reported first-quarter fiscal 2016 earnings per American Depositary Share (ADS) of 58 cents, up 13.7% from the year-ago quarter.
AGN: 249.61 (-3.41), PGNX: 6.68 (+0.01), RDY: 44.82 (unch)

UCB to Expand Cimzia Label Based on Positive Phase III Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 15, 1:50PM CDT
UCB S.A. (UCBJF) announced positive results from a phase III study on Cimzia for rheumatoid arthritis in DMARD-naive patients at high risk of disease progression.
VRX: 24.92 (+0.43), BIOD: 0.39 (unch)

Immunomedics' Drug Gets Fast Track Status for Lung Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 18, 3:39PM CDT
Immunomedics, Inc. (IMMU) announced that the FDA has granted fast track designation to its lead antibody-drug conjugate program sacituzumab govitecan for the treatment of patients suffering from metastatic non-small cell lung cancer.
VRX: 24.92 (+0.43), IMMU: 2.92 (+0.08), PFE: 34.98 (-0.17)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vitamin Angels Drives Global Nutrition Advancements

Navigating the Waters of Global Nutrition Bet you never thought a vitamin program could spearhead the front lines of healthcare, huh? Vitamin Angels are grinding away under the radar, shifting the landscape for maternal and child nutrition. At the heart of it all is their vision to make UNIMMAP multiple micronutrient supplementation (MMS) a staple in the global playbook....

Gong, Agentforce, Avoma Crowned 2026 CI Champions

Diving Deep into Conversation Intelligence There's a lot to unpack when three software titans hog the spotlight, and that's exactly what's happening in the world of conversation intelligence this year. It's like we've hit the jackpot with Gong, Agentforce Sales, and Avoma carving out their turf as the 2026 Champions, according to the venerable Info-Tech Research Group....

OCI N.V. Secures a Win in Court; EGM Proceeds as Planned

OCI Dodges a Bullet in Amsterdam Court Stepping into the courtroom drama, OCI N.V. just took home a win as the Amsterdam Court of Appeal's Enterprise Chamber gave them a clean bill of health, kicking out the inquiry request from VEB and a bunch of other shareholders. The judges weren't convinced there was anything fishy going on, so they tossed the inquiry petition and...

Wally Disrupts Dental Industry with $25M Funding

A New Breath of Fresh Air for Dental Care Dental visits—a tedious, costly affair we've all dreaded. So, when Wally rolls out an overhaul in this stale landscape, it's worth taking notice. With $25 million in their pockets from Series A funding led by Maveron, Wally's swaggering in with a plan to flip the script on dental care across the nation. Redefining the Dental...

HelloNation Brings 'Edvertising' to NC REALTORS® Event

HelloNation's Bold Step into Real Estate Networking October 8th to the 11th is shaping up to be a pivotal few days in Wilmington, North Carolina. Here’s the scoop: HelloNation, known for its innovative 'edvertising' model, is joining the bustling crowd at the 2026 NC REALTORS® Convention. This isn’t just any get-together—it's the grandest annual jamboree for real...

Duke Energy's Cost-Protection Plan Shields Ratepayers

Shielding Customers From Data Center Costs Let's get right into the thick of it: Duke Energy's latest move is a strategic one, shrouded in industry terms but with a real impact on regular folks' wallets. The company's agreement with heavyweights like Amazon, Google, and Meta aims to protect existing customers in North Carolina from getting hit with the costs of powering...

Merit Expands in New York with Bold Acquisition Move

Merit Financial's Growth Trajectory Takes a Leap You watch the movers and shakers in this game long enough, and you start to see patterns. Merit Financial Advisors is one of those juggernauts you'd better keep an eye on. These folks just scooped up Moldenhauer & Associates—a firm that's been a staple in Orchard Park, New York—for a cool $1.1 billion worth of client...

Decoding CarBravo-Certified vs Traditional Used Cars

What’s Behind Door Number One: CarBravo Certification When you walk onto a car lot these days, it's a mixed bag: shiny badges boasting certifications or basic used car signage. For anyone who's spent time around cars, two types stick out—there’s your CarBravo-certified vehicles and your good ol' used cars. Now, Marissa McCoy and Jill Maniaci from Heidebreicht...

C3EL Expands Federal Footprint with Strategic Contracts

Pushing Boundaries in Federal Contracts What a ride C3EL's had in Government Fiscal Year 2026! Let me tell you, they’ve bagged a bunch of contracts that’d make any company’s mouth water. Kicking things off, they snagged a prime cybersecurity contract from the U.S. Air Force. Considering our current cybersecurity landscape, that's like striking gold. But they...

Ornellaia's 2026 Harvest: Adapting to Nature's Whims

A Year Marked by Weather's Unpredictable Dance Nobody said making wine was a walk in the park, and the folks at Ornellaia know better than most how to roll with whatever nature throws their way. The 2026 harvest story is as much about unlocking the secrets of the soil as it is about navigating the quirks of the weather. Situated in Bolgheri, Italy, this year's vintage...